filmov
tv
Infection generates natural immunity

Показать описание
Which seems good and long lasting and cheap, lots of evidence below.
Biological studies
Dan et al (2021) Science, Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
95% of participants tested retained immune memory at about 6 months after having COVID-19
More than 90% of participants had CD4+ T-cell memory at 1 month,
and 6–8 months after having COVID-19
Wang et al (2021) Science, Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Previous SARS-CoV-2 infection,
with an ancestral variant produce antibodies that cross-neutralise emerging variants of concern with high potency
Epidemiological studies
Hansen et al (2021) Lancet, Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
People who had had COVID-19 previously were around 80·5% protected against reinfection
Pilz et al (2021) European Journal of Clinical Investigation, SARS-CoV-2 re-infection risk in Austria
Sheehan et al (2021) Clinical Infectious Diseases, Reinfection rates among patients who previously tested positive for COVID-19: a retrospective cohort study
Shrestha et al (2021) Preprint, Necessity of COVID-19 vaccination in previously infected individuals
Retrospective cohort study in the USA,
People who had had COVID-19 previously were 100% protected against reinfection
Gazit et al (2021) Preprint, Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
Kojima et al (2021) Preprint, Incidence of severe acute respiratory syndrome coronavirus-2 infection among previously infected or vaccinated employees
Laboratory staff routinely screened for SARS-CoV-2,
people who had had COVID-19 previously were 100% protected against reinfection
Clinical studies
Large, multicentre, prospective cohort study
Previous COVID-19 diagnosis,
84% decreased risk of infection
Letizia et al (2021) Lancet, Respiratory Medicine, SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study
Prospective cohort of US Marines,
seropositive young adults were 82% protected against reinfection
Adnan et al (2021) Clinical Infectious Diseases, Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing
N = 9,119, serial tests
Reinfection rates, 0.7%
So
Risk of repeat SARS-CoV-2 infection decreased by 80·5–100% among those who had had COVID-19
Protection from reinfection is strong and persists for more than 10 months of follow-up, (Hansen et al 2021 Lancet)
Turner, et al Nature, SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Madhuumita et al, Plos One, T cell response to SARS-CoV-2 infection in humans: A systematic review
SARS-CoV-2 infection induces specific and durable T-cell immunity,
Nina et al, (2020) Nature, SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Memory B-cell response to SARS-CoV-2 evolves between 1·3 and 6·2 months after infection, which is consistent with longer-term protection
Some people who have recovered from COVID-19 might not benefit from COVID-19 vaccination
One study found that previous COVID-19 was associated with increased adverse events following vaccination with Pfizer
In Switzerland, proof of recovered infection, in the past 12 months are considered equally protected as fully vaccinated,
Biological studies
Dan et al (2021) Science, Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
95% of participants tested retained immune memory at about 6 months after having COVID-19
More than 90% of participants had CD4+ T-cell memory at 1 month,
and 6–8 months after having COVID-19
Wang et al (2021) Science, Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Previous SARS-CoV-2 infection,
with an ancestral variant produce antibodies that cross-neutralise emerging variants of concern with high potency
Epidemiological studies
Hansen et al (2021) Lancet, Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
People who had had COVID-19 previously were around 80·5% protected against reinfection
Pilz et al (2021) European Journal of Clinical Investigation, SARS-CoV-2 re-infection risk in Austria
Sheehan et al (2021) Clinical Infectious Diseases, Reinfection rates among patients who previously tested positive for COVID-19: a retrospective cohort study
Shrestha et al (2021) Preprint, Necessity of COVID-19 vaccination in previously infected individuals
Retrospective cohort study in the USA,
People who had had COVID-19 previously were 100% protected against reinfection
Gazit et al (2021) Preprint, Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
Kojima et al (2021) Preprint, Incidence of severe acute respiratory syndrome coronavirus-2 infection among previously infected or vaccinated employees
Laboratory staff routinely screened for SARS-CoV-2,
people who had had COVID-19 previously were 100% protected against reinfection
Clinical studies
Large, multicentre, prospective cohort study
Previous COVID-19 diagnosis,
84% decreased risk of infection
Letizia et al (2021) Lancet, Respiratory Medicine, SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study
Prospective cohort of US Marines,
seropositive young adults were 82% protected against reinfection
Adnan et al (2021) Clinical Infectious Diseases, Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing
N = 9,119, serial tests
Reinfection rates, 0.7%
So
Risk of repeat SARS-CoV-2 infection decreased by 80·5–100% among those who had had COVID-19
Protection from reinfection is strong and persists for more than 10 months of follow-up, (Hansen et al 2021 Lancet)
Turner, et al Nature, SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Madhuumita et al, Plos One, T cell response to SARS-CoV-2 infection in humans: A systematic review
SARS-CoV-2 infection induces specific and durable T-cell immunity,
Nina et al, (2020) Nature, SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Memory B-cell response to SARS-CoV-2 evolves between 1·3 and 6·2 months after infection, which is consistent with longer-term protection
Some people who have recovered from COVID-19 might not benefit from COVID-19 vaccination
One study found that previous COVID-19 was associated with increased adverse events following vaccination with Pfizer
In Switzerland, proof of recovered infection, in the past 12 months are considered equally protected as fully vaccinated,
Комментарии